Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX).

Full DD Report for CPRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CPRX)

Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2018 Results - Earnings Call Transcript
Catalyst Pharmaceutical, Inc. (CPRX) Q1 2018 Earnings Conference Call May 10, 2018 08:30 A.M. ET Executives Alicia Grande - VP, CFO and Treasurer Patrick J. McEnany - Co-Founder, Chairman, President and CEO Steven R. Miller - COO and CSO Gary Ingenito - CMO and Head of Regulato...
Source: SeekingAlpha
Date: May, 10 2018 10:20
Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update
CORAL GABLES, Fla., May 09, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported fi...
Source: GlobeNewswire
Date: May, 09 2018 16:12
Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, May 10th, 2018
CORAL GABLES, Fla., May 02, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today ...
Source: GlobeNewswire
Date: May, 02 2018 08:03
Institutional Investors Give Their Vote Of Confidence For Catalyst Pharmaceuticals
Shares of Catalyst Pharmaceuticals ( CPRX ) have declined some 36% since the start of 2018, in response to the refusal to file letter that the FDA issued the company. The clinical trials that were completed all had relatively small sample sizes; as such, the FDA wanted to acquire more data o...
Source: SeekingAlpha
Date: April, 30 2018 19:02
Catalyst Pharmaceuticals Introduces New Corporate Website
CORAL GABLES, Fla., April 24, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
Source: GlobeNewswire
Date: April, 24 2018 08:03
Report: Developing Opportunities within Clean Energy Fuels, Catalyst Pharmaceuticals, Qorvo, Brunswick, DCT Industrial Trust, and Radius Health - Future Expectations, Projections Moving into 2018
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clean Energy Fuels Corp. (NASDAQ:CLNE), Catalyst Pharmaceuticals, Inc. (...
Source: GlobeNewswire
Date: April, 20 2018 08:10
Enrollment underway in late-stage study of Catalyst Pharma's Firdapse in subtype of myasthenia gravis
The first patient has been enrolled in a Phase 3 clinical trial, MSK-002 , assessing Catalyst Pharmaceuticals' ( CPRX +0.4% ) Firdapse (amifampridine phosphate) in patients with MuSK antibody-positive myasthenia gravis  (MG), an autoimmune disorder characterized by weakness and ra...
Source: SeekingAlpha
Date: April, 19 2018 11:05
Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis
CORAL GABLES, Fla., April 19, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
Source: GlobeNewswire
Date: April, 19 2018 08:03
Midday Gainers / Losers (4/4/2018)
Gainers: TENX +75% . RXII +25% . INTX +19% . VCEL +18% . PTI +16% . RTTR +15% . TOPS +17% . CPRX +15% . FTD +13% . OSN +13% . More news on: Tenax Therapeutics, Inc., RXI Pharmaceuticals Corporation, Intersections, Inc., Stocks on the move, , Read more ....
Source: SeekingAlpha
Date: April, 04 2018 12:41
3 Things In Biotech, April 2: Catalyst Pharm Goes, Pfizer Flows, MediciNova Woes
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: April, 03 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-172.882.902.97012.875227,644
2018-08-162.892.892.922.80219,231
2018-08-152.892.882.912.825245,781
2018-08-142.952.892.99052.83438,051
2018-08-133.002.9453.052.89600,836

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1726,99954,59349.4551Short
2018-08-1621,90171,00730.8434Cover
2018-08-1528,01777,45036.1743Short
2018-08-1456,694142,97339.6536Short
2018-08-13114,800265,77443.1946Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CPRX.


About Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)

Logo for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)

Not available

 

Contact Information

 

 

Current Management

  • Patrick McEnany / CEO
  • Alicia Grande / CFO

Current Share Structure

  • Market Cap: $345,614,273 - 05/15/2018
  • Issue and Outstanding: 102,556,164 - 03/09/2018

 


Recent Filings from (NASDAQ: CPRX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: CPRX)

Daily Technical Chart for (NASDAQ: CPRX)


Stay tuned for daily updates and more on (NASDAQ: CPRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CPRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CPRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CPRX and does not buy, sell, or trade any shares of CPRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/